Vir Gross Profit Margin vs Pretax Profit Margin Analysis
VIR Stock | USD 7.34 0.03 0.41% |
Vir Biotechnology financial indicator trend analysis is much more than just breaking down Vir Biotechnology prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Vir Biotechnology is a good investment. Please check the relationship between Vir Biotechnology Gross Profit Margin and its Pretax Profit Margin accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vir Biotechnology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in Vir Stock, please use our How to Invest in Vir Biotechnology guide.
Gross Profit Margin vs Pretax Profit Margin
Gross Profit Margin vs Pretax Profit Margin Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Vir Biotechnology Gross Profit Margin account and Pretax Profit Margin. At this time, the significance of the direction appears to have totally related.
The correlation between Vir Biotechnology's Gross Profit Margin and Pretax Profit Margin is 1.0. Overlapping area represents the amount of variation of Gross Profit Margin that can explain the historical movement of Pretax Profit Margin in the same time period over historical financial statements of Vir Biotechnology, assuming nothing else is changed. The correlation between historical values of Vir Biotechnology's Gross Profit Margin and Pretax Profit Margin is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Gross Profit Margin of Vir Biotechnology are associated (or correlated) with its Pretax Profit Margin. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Pretax Profit Margin has no effect on the direction of Gross Profit Margin i.e., Vir Biotechnology's Gross Profit Margin and Pretax Profit Margin go up and down completely randomly.
Correlation Coefficient | 1.0 |
Relationship Direction | Positive |
Relationship Strength | Very Strong |
Gross Profit Margin
Pretax Profit Margin
Most indicators from Vir Biotechnology's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Vir Biotechnology current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vir Biotechnology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in Vir Stock, please use our How to Invest in Vir Biotechnology guide.As of 12/25/2024, Enterprise Value is likely to grow to about 1.8 B, though Tax Provision is likely to grow to (55.4 M).
2021 | 2022 | 2023 | 2024 (projected) | Interest Income | 439K | 28.1M | 82.4M | 86.5M | Net Interest Income | 439K | 28.1M | 82.4M | 86.5M |
Vir Biotechnology fundamental ratios Correlations
Click cells to compare fundamentals
Vir Biotechnology Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Vir Biotechnology fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 512.1M | 918.8M | 2.0B | 2.8B | 1.9B | 1.3B | |
Other Current Liab | 46.9M | 83.9M | 226.4M | 469.7M | 91.2M | 147.1M | |
Total Current Liabilities | 59.2M | 99.1M | 341.2M | 511.0M | 175.4M | 194.6M | |
Total Stockholder Equity | 423.9M | 716.9M | 1.4B | 2.1B | 1.6B | 941.7M | |
Other Liab | 28.9M | 36.3M | 47.6M | 89.3M | 102.6M | 107.8M | |
Net Tangible Assets | 371.3M | 666.1M | 1.4B | 2.0B | 2.3B | 2.4B | |
Property Plant And Equipment Net | 16.3M | 79.9M | 130.1M | 188.2M | 167.2M | 94.1M | |
Net Debt | (109.1M) | (370.0M) | (214.3M) | (720.7M) | (130.3M) | (136.8M) | |
Retained Earnings | (368.5M) | (667.2M) | (138.6M) | 377.2M | (237.8M) | (249.7M) | |
Accounts Payable | 5.9M | 5.1M | 6.5M | 6.4M | 6.3M | 6.5M | |
Cash | 109.3M | 436.6M | 347.8M | 848.6M | 254.8M | 350.9M | |
Non Current Assets Total | 109.1M | 146.4M | 391.4M | 283.0M | 330.8M | 219.0M | |
Non Currrent Assets Other | 15.8M | 15.7M | (87.1M) | (228.5M) | 18.9M | 19.8M | |
Other Assets | 9.2M | 77.7M | 9.8M | 21.2M | 1.0 | 0.95 | |
Cash And Short Term Investments | 383.4M | 736.9M | 708.1M | 2.4B | 1.5B | 949.0M | |
Common Stock Shares Outstanding | 107.6M | 119.2M | 133.4M | 134.8M | 134.1M | 129.3M | |
Short Term Investments | 274.1M | 300.3M | 360.3M | 1.6B | 1.3B | 1.3B | |
Liabilities And Stockholders Equity | 512.1M | 918.8M | 2.0B | 2.8B | 1.9B | 1.3B | |
Non Current Liabilities Total | 28.9M | 102.8M | 181.2M | 213.1M | 153.4M | 150.7M | |
Capital Surpluse | 14.7M | 793.1M | 1.4B | 1.6B | 1.8B | 1.9B | |
Capital Lease Obligations | 237K | 70.4M | 133.6M | 123.8M | 124.5M | 71.1M | |
Other Current Assets | 13.4M | 53.1M | 81.6M | 117.0M | 24.9M | 47.6M | |
Other Stockholder Equity | 281.0M | 1.4B | 1.6B | 1.7B | 1.8B | 1.1B | |
Total Liab | 88.1M | 201.9M | 522.4M | 724.1M | 328.8M | 401.8M | |
Net Invested Capital | 423.9M | 716.9M | 1.4B | 2.1B | 1.6B | 941.7M | |
Property Plant And Equipment Gross | 16.3M | 17.9M | 130.1M | 188.2M | 201.1M | 211.2M | |
Total Current Assets | 403.0M | 772.4M | 1.6B | 2.5B | 1.6B | 1.1B | |
Accumulated Other Comprehensive Income | (601K) | (1.3M) | (1.1M) | (9.1M) | (815K) | (855.8K) | |
Non Current Liabilities Other | 12.9M | 95.8M | 25.4M | 32.8M | 40.2M | 35.9M | |
Net Working Capital | 343.8M | 673.3M | 1.2B | 2.0B | 1.4B | 929.9M | |
Short Term Debt | 237K | 3.6M | 3.9M | 4.1M | 12.9M | 13.5M | |
Intangible Assets | 35.7M | 33.8M | 33.3M | 32.8M | 22.6M | 26.4M | |
Property Plant Equipment | 16.3M | 17.9M | 130.1M | 188.2M | 216.4M | 227.2M | |
Current Deferred Revenue | 6.2M | 6.5M | 98.2M | 15.5M | 64.9M | 36.7M |
Pair Trading with Vir Biotechnology
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Vir Biotechnology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Vir Biotechnology will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Vir Biotechnology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Vir Biotechnology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Vir Biotechnology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Vir Biotechnology to buy it.
The correlation of Vir Biotechnology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Vir Biotechnology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Vir Biotechnology moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Vir Biotechnology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Vir Stock Analysis
When running Vir Biotechnology's price analysis, check to measure Vir Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vir Biotechnology is operating at the current time. Most of Vir Biotechnology's value examination focuses on studying past and present price action to predict the probability of Vir Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vir Biotechnology's price. Additionally, you may evaluate how the addition of Vir Biotechnology to your portfolios can decrease your overall portfolio volatility.